A clinical trial of 676 patients - who had previously undergone treatment (some with advanced stages (3/4) tumors) indicated a near doubling of life expectancy. 12-month survival increased from 25% to 46% and 24-month survival increased from 14% to 24%.
The new drug (Ipilimumab) acts as a targeted T4 cell suppressant (immunosuppressive affect) for patients that carry a specific HLA gene. Data on the percentage of MM treated patients with this gene was not covered in the releases.
Although the drug has not achieved FDA approval, it is available at (75) cancer centers in the U.S. on a "compassionate-use trial" basis.
In addition to treatment of MM, there is indication that it may be a powerful therapy for other advanced cancers of the breast, prostate, and lung.
This blogger wonders if we are on the edge of "silver bullet" cancer therapy-what a hopeful thought!
Contact us for all of your underwriting needs!
Website: www.advanceduwsolutions.com
Email Us: newbiz@advanceduwsolutions.com
Connect with the Prez;
www.linkedin.com/in/tddavisaus
http://twitter.com/TraciDavisAUS
